Reply to ‘Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [11C]-PHNO PET study.’

2021 ◽  
Author(s):  
Pedro Barbosa ◽  
Bimali Hapuarachchi ◽  
Atbin Djamshidian ◽  
Kate Strand ◽  
Andrew J. Lees ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Impulse Control ◽  
Ventral Striatum ◽  
Impulse Control Disorders ◽  
Dopamine D3 Receptor ◽  
D3 Receptor ◽  
Dopamine D3

Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson’s disease patients

2016 ◽  
Vol 30 ◽  
pp. 13-17 ◽  
Author(s):  
Soumya Krishnamoorthy ◽  
Roopa Rajan ◽  
Moinak Banerjee ◽  
Hardeep Kumar ◽  
Gangadhara Sarma ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Impulse Control ◽  
Impulse Control Disorders ◽  
Dopamine D3 Receptor ◽  
D3 Receptor ◽  
Dopamine D3

scholarly journals Lower nucleus accumbens α-synuclein load and D3 receptor levels in Parkinson's disease with impulsive compulsive behaviours

Brain ◽  
2019 ◽  
Vol 142 (11) ◽  
pp. 3580-3591
Author(s):  
Pedro Barbosa ◽  
Bimali Hapuarachchi ◽  
Atbin Djamshidian ◽  
Kate Strand ◽  
Andrew J Lees ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Nucleus Accumbens ◽  
Ventral Striatum ◽  
Alpha Synuclein ◽  
Dopamine D3 Receptor ◽  
Post Mortem ◽  
D3 Receptor ◽  
Dopamine D3 ◽  
Dopaminergic Stimulation

Impulsive compulsive behaviours (ICBs) are common in Parkinson’s disease. In a post-mortem study, Barbosa et al. show that Parkinson’s disease patients with ICBs have lower alpha-synuclein load and dopamine D3 receptor levels in the nucleus accumbens. Excessive dopaminergic stimulation and relative preservation of the ventral striatum may contribute to ICBs.

scholarly journals Dopamine D3 Receptor Ligand Suppresses the Expression of Levodopa-Induced Dyskinesia in Nonhuman Primate Model of Parkinson's Disease

2021 ◽  
Author(s):  
Thomas Oh ◽  
Elyas Daadi ◽  
Jeffrey Kim ◽  
Etienne Daadi ◽  
Peng-Jen Chen ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Partial Agonist ◽  
Nigrostriatal System ◽  
Dopamine D3 Receptor ◽  
D3 Receptor ◽  
Lead Compound ◽  
Primate Model ◽  
Medical Needs ◽  
Dopamine D3

Abstract Parkinson’s disease (PD) is a complex multisystem, chronic and so far incurable disease with significant unmet medical needs. The incidence of PD increases with aging and the expected burden will continue to escalate with our aging population. Since its discovery in the 1961 levodopa remains the gold standard pharmacotherapy for PD. However, the progressive nature of the neurodegenerative process in and beyond the nigrostriatal system causes a multitude of side effects, including levodopa-induced dyskinesia within 5 years of therapy. Attenuating dyskinesia has been a significant challenge in the clinical management of PD. We report on a small molecule that eliminates the expression of levodopa-induced dyskinesia and significantly improves PD-like symptoms. The lead compound PD13R we discovered is a dopamine D3 receptor partial agonist with high affinity and selectivity, orally active and with desirable drug-like properties. Future studies are aimed at developing this lead compound for treating PD patients with dyskinesia.

Sign in / Sign up

Export Citation Format

Share Document